Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CLN-978 |
| Synonyms | |
| Therapy Description |
CLN-978 is a bispecific antibody that targets CD19 and CD3, potentially resulting in increased antitumor immune activity (Cancer Res (2022) 82 (12_Supplement): 2077). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CLN-978 | CLN 978|CLN978 | CD19 Antibody 21 CD3 Antibody 119 | CLN-978 is a bispecific antibody that targets CD19 and CD3, potentially resulting in increased antitumor immune activity (Cancer Res (2022) 82 (12_Supplement): 2077). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05879744 | Phase I | CLN-978 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | Active, not recruiting | USA | 0 |